Dx Deals: Outreach Deals by Quest, Labcorp Are Still Ramping Up
Though the two national players have closed dozens of such deals over the past decade, much runway for new transactions apparently remains
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Though the two national players have closed dozens of such deals over the past decade, much runway for new transactions apparently remains
From - National Intelligence Report
If you've been in the clinical labs business for a while, you probably appreciate the wisdom behind this ancient Chinese curse. 2018 is shaping up to be a very…
From - Laboratory Industry Report
A pair of tumor tests highlights the list of new FDA approvals from mid-November through December, including…
From - G2 Compliance Advisor
While the feds have made urine drug testing of opioid drug patients their number one target for lab-related False Claims Act (FCA) charges this year, nuclear stress tests …
From - G2 Compliance Advisor
SITUATION
Fictional Med (FM), a large physician-owned clinic, is one of your lab's biggest customers. So your heart sinks when…
From - Laboratory Industry Report
The phrase "most exciting FDA laboratory developed test approvals of the year" is no longer an oxymoron. The agency remains glacial in tempo…
From - National Intelligence Report
Although the OIG has its flaws, lack of transparency is not among them. Exhibit A: the agency's ongoing list of top 10 management and…